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Standard radiation therapy for patients undergoing primary chemosensitized radiation for
carcinomas of the cervix usually consists of external beam radiation followed by an intra-
cavitary brachytherapy boost. On occasion, the brachytherapy boost cannot be performed
due to unfavorable anatomy or because of coexisting medical conditions.We examined the
safety and efﬁcacy of using CyberKnife stereotactic body radiotherapy (SBRT) as a boost
to the cervix after external beam radiation in those patients unable to have brachytherapy
to give a more effective dose to the cervix than with conventional external beam radiation
alone. Six consecutive patients with anatomic or medical conditions precluding a tandem
and ovoid boost were treated with combined external beam radiation and CyberKnife boost
to the cervix. Five patients received 45Gy to the pelvis with serial intensity-modulated radi-
ation therapy boost to the uterus and cervix to a dose of 61.2Gy.These ﬁve patients received
an SBRT boost to the cervix to a dose of 20Gy in ﬁve fractions of 4Gy each. One patient
was treated to the pelvis to a dose of 45Gy with an external beam boost to the uterus and
cervix to a dose of 50.4Gy. This patient received an SBRT boost to the cervix to a dose
of 19.5Gy in three fractions of 6.5Gy. Five percent volumes of the bladder and rectum
were kept to ≤75Gy in all patients (i.e., V75Gy≤ 5%). All of the patients remain locally
controlled with no evidence of disease following treatment. Grade 1 diarrhea occurred in
4/6 patients during the conventional external beam radiation. There has been no grade 3
or 4 rectal or bladder toxicity. There were no toxicities observed following SBRT boost.
At a median follow-up of 14months, CyberKnife radiosurgical boost is well tolerated and
efﬁcacious in providing a boost to patients with cervix cancer who are unable to undergo
brachytherapy boost. Further follow-up is required to see if these results remain durable.
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INTRODUCTION
Standard radiation therapy for cervical carcinoma patients under-
going primary chemosensitized radiation therapy usually consists
of external beam therapy followed by an intracavitary brachyther-
apy boost (Eifel et al., 2004). Using this approach, the brachyther-
apy serves to provide a tumorical dose to the cervix while limiting
the dose to surrounding anatomy, such as the bladder and rectum,
which have a lower dose tolerance. Typically, external beam radia-
tion delivers a dose of approximately 45Gy to encompass the pri-
mary tumor and regional pelvic lymph nodes. The brachytherapy
boost results in a total dose ranging from 70 to 95Gy to the pri-
mary tumor (assuming an alpha/beta ratio of 10Gy), depending
on tumor stage and anatomy.
In certain circumstances, the brachytherapy boost may not
be feasible due to coexisting medical conditions, unfavorable
anatomy, or patient refusal to undergo the procedure. In these
cases, a higher dose of external beam radiation (EBRT) may
be given, but the total dose delivered is usually less than
when a brachytherapy procedure is performed. Predictably, the
results when brachytherapy is not performed are inferior. For
instance, Barraclough et al. delivered a total dose of 54–70Gy
through the addition of an EBRT boost to patients unable to
receive the brachytherapy boost. The majority of patients devel-
oped a central recurrence in less than 5 years and had a 5-
year overall survival rate of 49.3% (Barraclough et al., 2008).
This compares unfavorably to combined external beam therapy
with a brachytherapy boost where 5-year local control and sur-
vival are in the 60–70% range (Rose et al., 1999; Eifel et al.,
2004).
Brachytherapy takes advantage of the inverse square law in that
high doses of radiation are given to the target (cervix in this case)
and low doses are given to the normal anatomy by moving them
out of the way with packingmaterial exploiting the rapid dose fall-
off and inhomogeneous dose distribution seen with brachyther-
apy. Stereotactic body radiotherapy (SBRT) provides a poten-
tial alternative method to boost the cervix in those cases where
brachytherapy is not performed. SBRT emulates brachytherapy
by having multiple non-coplanar beams intersecting at the target
(cervix) delivering a high therapeutic dosewhileminimizing beam
traversal through normal anatomy reducing dose to these areas. By
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prescribing to a speciﬁc isodose line (i.e., the dose line that covers
the volume of interest), the tumor receives an inhomogeneous
dose similar to that delivered with brachytherapy. Technological
advances using the CyberKnife (Accuray Incorporated, Sunnyvale,
CA, USA), a robotic radiation delivery system, allow more precise
targeting and delivery of radiation to the cervix while sparing nor-
mal anatomy compared to conventional radiation. This potentially
allows dose escalation to the cervix to a dose comparable to the
brachytherapy boost while respecting the normal tissue tolerance
of the bladder and rectum. The CyberKnife’s use of a large number
of small radiation beams also allows delivery of an inhomogeneous
dose distribution similar to that of brachytherapy (Fuller et al.,
2008).
Another important aspect of CyberKnife delivered SBRT to
the cervix is motion tracking. The cervix is not a ﬁxed pelvic
organ, rather one that is subject to movement during treat-
ment. For example, a study from the University of California at
San Diego showed that the cervix can move as much as 18mm
during intensity-modulated radiation therapy (IMRT) treatment
(Haripotepornkul et al., 2011); other studies of cervical motion
have shown similar movement (Hombaiah et al., 2006; Taylor and
Powell, 2008). Given the large movement possible, continuous
tracking of the cervix during treatment is imperative in ensur-
ing proper delivery of dose to the tumor particularly when giving
larger than conventional daily doses of radiation as is the case with
the SBRT. Lastly, since SBRT is given in a week, the total treat-
ment time frame is comparable to external beam therapy with a
brachytherapy boost thus limiting the deleterious effect observed
in prolonged treatments extending beyond 7weeks (Fyles et al.,
1992; Girinsky et al., 1993; Lanciano et al., 1993; Perez et al., 1995;
Petereit et al., 1995).
In this report, we present preliminary local control results on
the treatment of six patients with cervical cancer who did not
have a brachytherapy boost and were treated with an SBRT boost
resulting in a total dose of 77–85Gy to the cervix.
MATERIALS AND METHODS
This is a retrospective chart review of cervical cancer patients
treated with combined external beam radiation and SBRT boost to
the cervix atWinthrop-UniversityHospital from3/2009 to 8/2011.
All patients gave informed consent for the treatment. All patients
received a series of conventionally fractionated radiation therapy
followed by an SBRT dose. One of two dose schemes was used.
Early in our program of treating cervical cancer patients with
an SBRT boost the conventionally fractionated treatment con-
sisted of a 45Gy dose to the pelvis using 15MV photons followed
by an IMRT boost to the cervix and uterus to a total delivered
conventionally fractionated radiation therapy dose of 50.4Gy.
Subsequently, we modiﬁed our treatment so that the convention-
ally fractionated treatment began with a dose of 45Gy to the pelvis
using 15MV photons followed by two IMRT boosts, one to the
uterus and cervix that increased the delivered dose to 50.4Gy and
a second IMRT boost to the cervix alone resulting in a total deliv-
ered conventionally fractionated radiation therapy dose of 61.2Gy.
The bladder and rectum dose constraints required no more than
5% of their volume to receive 70Gy (i.e.,V70Gy≤ 5%). However,
in cases where the tumor’s anatomical location necessitated a high
dose to the bladder and/or rectum a point dose of up to 75Gy was
allowed.
Following conventionally fractionated radiation therapy,
patients had three to four gold ﬁducial markers placed into the
cervix andupper vagina. Fiducial placement beganwith a lidocaine
gel and a betadine prep andproceededunder direct visualization in
the lithotomy position. The ﬁducials were placed into the cervix
at the 3 and 9 o’clock position and superiorly into the vaginal
fornices in an orientation to prevent overlap in the plane of the
X-ray imaging. Treatment planning CT scans at a slice thickness
of 1.25mm and an MRI scan using a slice thickness of 1–2mm
were performed 1week after ﬁducial placement. All pretreatment
imaging was performed with the patient in the same position used
for SBRT delivery. The pulse sequence used for MRI acquisition
was gradient echo which maximized the signal void attributable
to the ﬁducials and allowed for clear visualization of the ﬁducials
in the MR image. This allowed for the fusion of the MR and CT
data sets using the ﬁducials. The gross tumor volume (GTV) was
contoured by the attending radiation oncologist using both CT
and MRI images to accurately delineate the cervical anatomy and
to deﬁne the interface between the cervix and anterior wall of the
rectum.
All patients received SBRT boost using the CyberKnife system
(Accuray Incorporated, Sunnyvale, CA, USA) which consists of a
6-MV linear accelerator mounted on a robotic arm. Using this
system two orthogonal kilovoltage X-ray imagers provide real-
time image guidance and automatic correction for movement of
the cervix throughout the treatment. There were typically 150–
200 non-coplanar beams delivered during each treatment session.
Target tracking and patient positioning were accomplished by reg-
istering the location of the ﬁducial markers in the real-time images
to their planning CT location. Imaging was performed approxi-
mately once perminute. The robotic delivery system automatically
changes the linear accelerator’s position to correct for both rota-
tional and translationalmovement of the patient and cervix during
treatment. The total clinical accuracy for treatment is less than
1mm (Kilby et al., 2010). Treatments were delivered on three or
ﬁve consecutive days. Patients had a bowel prep including Dulco-
lax (Boehringer, Germany) and a ﬂeet enema on the morning of
each treatment. Additionally, patients received 1500mg of amifos-
tine (MedImmune, LLC, Gaithersburg,MD, USA) mixed in saline
as a rectal suppository at least 15–20min prior to each treatment
as a radioprotectant.
For the lower conventionally fractionated dose (50.4Gy) the
SBRT boost to the cervix was 19.5Gy in three fractions of 6.5 Gy
each. For later patients who received a conventionally fractionated
dose of 61.2Gy the SBRT boost to the cervix was 20Gy in ﬁve
fractions of 4Gy each. In all cases, margins were 5mm laterally,
inferiorly and superiorly around the CTV. Themargins were 3mm
anteriorly and posteriorly to limit dose to the bladder and rectum.
Four of the six patients received systemic chemotherapy during
their radiation consisting of cisplatin at a dose of 40mg/m2.
Patients were followed at 3weeks after treatment and every
3months thereafter. Follow-up assessmentswere based onphysical
examination by the radiation oncologist and treating gyneco-
logic oncologist. Toxicities were scored based on radiation therapy
oncology group (RTOG) rectal and urinary toxicity criteria.
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RESULTS
Six consecutive cervical cancer patients were treated with com-
bined external beam radiation and SBRT boost to the cervix at
Winthrop-UniversityHospital from 3/2009 to 8/2011. Themedian
patient age was 80 years (range, 71–94 years). One patient refused
brachytherapy; all other patients were unable to receive a tandem
and ovoid brachytherapy boost because of either anatomic (n = 3)
or medical (n = 2) conditions. The ﬁrst patient treated received a
conventionally fractionated total dose of 50.4Gy followed by an
SBRT cervix boost of 19.5Gy delivered in three fractions. The ﬁve
subsequent patients received a conventionally fractionated total
dose of 61.2Gy followed by an SBRT cervix boost of 20Gy deliv-
ered in four fractions. Five percent volumes of the bladder and
rectum were kept to ≤70Gy (i.e., V75Gy≤ 5%) with the excep-
tion of maximal post doses up to 75Gy when necessary based
on tumor location (Table 2) Figure 1 shows a sample treatment
plan and dose volume histogram for a patient receiving an SBRT
boost of 20Gy. Observed cervix motion during treatment con-
sisted of drift in the anterior–posterior or superior–inferior axes;
sporadicmovement in the anterior–posterior, superior–inferior,or
left–right axes; or a combination of the two. This movement was
typically on the order of 10mm. Complete details on patient char-
acteristics and treatment parameters are summarized in Table 1.
In addition, Table 2 summarizes the maximal rectal and bladder
doses for each patient.
All patients tolerated the treatment well with no grade 3 or
higher urinary or rectal toxicities. Grade 1/2 urinary and bowel
toxicities occurred in four patients following conventional exter-
nal beam radiation. All of these symptoms resolved by the time
of SBRT boost. At a median follow-up of 14months (range, 1–
28months) fromcompletion of the SBRTboost there have beenno
additional RTOG toxicities. In addition, for the ﬁve patients with
aminimum of 12months follow-up all (100%) remain locally and
distantly controlled with no evidence of disease.
DISCUSSION
This report demonstrates the feasibility of using robotic SBRT as
an alternative to brachytherapy in cervical cancer patients unable
to undergo brachytherapy. The motivation for this series stems
from the markedly inferior reported outcomes for treatment of
such patients with a conventionally fractionated radiation boost
compared to brachytherapy. Speciﬁcally, Barraclough et al. (2008)
report on the treatment of 44 patients with a conventional external
beam boost to a total dose of 54–70Gy when intracavity therapy
could not be performed.At amedian 2.3 years follow-up, recurrent
disease was seen in 48% of patients with a median time to recur-
rence of 2.3 years. In addition, they observed late grade 3 toxicity in
2% of patients and late grade 1 and 2 bowel and bladder toxicities
in 41% of patients (Barraclough et al., 2008). The poor outcomes
in these studies are likely explained by the low doses given to the
paracervical region in order to respect tissue tolerance of the sur-
rounding anatomy such as the bladder and rectum. Indeed, most
institutions do not exceed 75–80Gy (combined external beam and
LDR brachytherapy dose) to the International Commission on
Radiological Units (ICRU) and Measurements bladder reference
point and 70–75Gy to the rectal reference point (Fletcher and
Hamberger, 1980; Eifel et al., 2004).
FIGURE 1 | (A) Representative treatment plan for a patient receiving an
SBRT boost of 20Gy delivered in four fractions. The orange line denotes the
planning target volume (PTV). (B) Dose volume histogram showing the
bladder (yellow) rectum (green), cervix (red), and PTV (purple).
Other studies using a conventional linear accelerator have
reported on a stereotactic boost for gynecologic cancers. In a case
study, Hsieh et al. (2010) reported on a patient who was unable to
undergo a brachytherapy boost due to multiple uterine myomas.
This patient received conventionally fractionated treatment to
54Gy followed by a helical tomotherapy boost of 24Gy and con-
current chemoradiotherapy. At 14months there was no evidence
of tumor recurrence. She had grade 1 nausea and vomiting during
treatment.
Molla et al. (2005) reported on a mixed population of 23
patients with either endometrial (n = 9) or cervical (n = 7) cancer
including two patients with local relapse. The patients received a
14Gy boost delivered with a linac-based micromultileaf collima-
tor in two fractions at 4–7 days intervals. At a median 12.6months
follow-up one previously irradiated relapse patient had a grade
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Table 1 | Patient characteristics and treatment summary.
Patient Stage Age (years) Reason unable to
receive brachytherapy
External RT (Gy) SBRT boost SBRT prescription
isodose line
1 IIB 83 Anatomy 50.4 6.5Gy×3 BED 77.67Gy 81
2 IIB 79 Medical 61.2 4.0Gy×5 BED 84.93Gy 82
3 IIB 75 Choice 61.2 4.0Gy×5 80
4 IIB 95 Medical 61.2 4.0Gy×5 81
5 IV 71 Anatomy 61.2 4.0Gy×5 80
6 IVA 76 Anatomy 61.2 4.0Gy×5 78
Table 2 | Summary of maximum rectal and bladder doses.
Patient Rectal max dose (Gy) Bladder max dose (Gy)
1 55.8 55.8
2 73.4 74.2
3 68.7 70.7
4 71.6 70.1
5 70.7 68.7
6 67.5 73.7
3 rectal bleed; no other patients developed severe urinary or
intestinal toxicity. One recurrence occurred 12months following
treatment for a cervical cancer patient; no other failures occurred.
Following a treatment planning comparison the authors con-
cluded that SBRT improved dose homogeneity to the PTV and
reduced rectal dose compared to brachytherapy. In a follow-up
publication, Jorcano et al. (2010) reported on 17 endometrial
and 9 cervical cancer patients treated with 45–50.4Gy EBRT fol-
lowed by a SBRT boost of 14Gy delivered in two fractions. Acute
toxicities consisted of 23 and 25% RTOG grade 3 or less uri-
nary and lower-gastrointestinal toxicities, respectively.At amedian
47months follow-up, the 3-year locoregional failure rate was 96%
for both endometrial and cervical patients. The authors conclude
that SBRT is feasible, well tolerated, and could be considered an
acceptable alternative to brachytherapy.
Limited reports on robotically delivered SBRT boost for cervi-
cal cancer patients have been published. The University of North
Carolina reported on treatment with a CyberKnife SBRT boost
of 25Gy in ﬁve fractions for a cervical cancer patient unable to
undergo brachytherapy. At a follow-up of 10months the patient
exhibited no RTOG toxicities, however, the patient died from pro-
gression of liver metastases. In the present series, one patient
received 50.4Gy with a 19.5Gy SBRT boost and the later ﬁve
patients received 60Gy with 20Gy SBRT boosts delivered using
robotic SBRT with real-time motion tracking. The inclusion of
motion tracking with CyberKnife delivered SBRT offers a more
accurate dose delivery to the target potentially accounting for
the lack of signiﬁcant toxicity in this patient population despite
a higher delivered dose than the conventional linear accelerator
delivered SBRT boost results (Molla et al., 2005; Jorcano et al.,
2010). In addition, the lack of any failure for the ﬁve patients with
aminimumof 12months follow-up is highly promising compared
to the EBRT boost results for which the cancer-speciﬁc overall
survival at 1 year was already only 80% (Barraclough et al., 2008).
CONCLUSION
This paper is the among the ﬁrst to report on using robotic SBRT
in patients with real-time motion tracking for the treatment of
locally advanced cervical cancer in patients who are unable to
undergo brachytherapy. These preliminary results suggest that
CyberKnife robotic SBRT is a safe and effective modality in the
treatment of cervix cancer for those patients unable to undergo
brachytherapy. Additional conﬁrmatory prospective studies with
larger numbers of patients and longer follow-up are required to
validate the durability of these results.
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